Assessing BioNTech (NasdaqGS:BNTX) Valuation After Founders’ Planned Exit And Weakening COVID-19 Revenues

BioNTech (NasdaqGS:BNTX) is back in focus after its co founders, CEO Ugur Sahin and Chief Medical Officer Ozlem Tureci, said they will leave by the end of 2026 to start a new early stage mRNA company.

See our latest analysis for BioNTech.

The leadership news comes after a weak run for the stock, with a 7 day share price return of 10.16% and a 30 day share price return of 16.63%. The 1 year total shareholder return of 8.32% and 3 year total shareholder return of 29.66% point to fading momentum from earlier periods as investors reassess growth prospects and risk around BioNTech’s vaccine and oncology transition.

If this leadership change has you reassessing biotech exposure, it could be worth scanning our screener of 33 healthcare AI stocks to find other names shaping the future of medicine.

With BioNTech now loss making, guiding 2026 revenue below 2025 levels, and trading at a discount to several analyst targets, you have to ask yourself: is there a mispriced long term story here, or is the market already factoring in the company’s future growth?

Most Popular Narrative: 81.8% Undervalued

BioNTech's most followed narrative pegs fair value at $499.94 per share versus the last close of $91.19, which puts a huge spotlight on its oncology pipeline.

"Amputation, intoxication and radiation". If students read about our current cancer treatment in 2050, they would probably date it back to 1960-70. Certainly not dating back to the time of AI, fusion reactors or recurring missiles. Sahin with his strength of pattern recognition and complexity reduction would certainly have started with an IT company, like many others. It is a stroke of luck that he has decided to fight against the Geissesl of humanity, because it is clear that medicine with AI, robotics and the breakdown of human metabolism into algorithms is facing a fundamental change. All of the recently developed molecules were not identified by trial and error after a long series of experiments but were designed in advance by the acquired AI forge. Precision, speed and cost-saving are coupled with impressive intermediate values in which gotistobart and pumitamig will be entitled to standard therapy. Pumitamig, which challenges the 30 billion blockbuster Keytruda in most of its range of indication, has been described as a quantum leap in lung cancer therapy with a response rate of 80% (compared to 40% for Keytruda). The patent will last until the mid-40s but is probably considered less relevant, as the complexity for generic manufacturers will be too high a threshold. Beibe therapy will provide about 300k turnover per patient compared to the 200k of Keytruda. That should be enough for now. Anything under $400 in 2030 would be a disappointment. A new ATH should definitely be in it :)

Read the complete narrative.

According to Hansimglueck, that $499.94 fair value leans heavily on ambitious oncology revenue, rich margins and a premium future earnings multiple. Want to see how those moving parts stack up against each other and how sensitive that value is to the assumptions behind them? The full narrative lays out the numbers driving that price tag.

Result: Fair Value of $499.94 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this hinges on oncology trials translating into approvals and meaningful revenue, and on leadership changes not disrupting execution or partner relationships.

Find out about the key risks to this BioNTech narrative.

Another View: Market Ratios Paint a Very Different Picture

That $499.94 user fair value paints BioNTech as deeply undervalued, but the current P/S of 6.7x tells a more cautious story. It sits below the US biotechs average of 11.6x, yet above both the peer average of 5.8x and the fair ratio of 5.7x, so is the discount really as large as it looks?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Looking for more investment ideas?

If this BioNTech story has sharpened your focus, do not stop here. The screener can help you uncover other ideas that fit your style and risk comfort.

• Target steady cash flow potential and resilient businesses by running your own search through our 14 dividend fortresses that aim to keep income front and center.
• Hunt for quality at a measured price by filtering companies through a 48 high quality undervalued stocks that line up fundamentals with market expectations.
• Prioritize resilience and sleep easier at night by scanning 68 resilient stocks with low risk scores that score well on risk checks and financial strength.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com